Lipocine Inc. (LPCN)

NASDAQ: LPCN · IEX Real-Time Price · USD
2.90
-0.08 (-2.62%)
At close: Sep 27, 2023, 4:00 PM
3.25
+0.35 (12.07%)
After-hours: Sep 27, 2023, 7:27 PM EDT
-2.62%
Market Cap 15.42M
Revenue (ttm) 54,990
Net Income (ttm) -12.06M
Shares Out 5.32M
EPS (ttm) -2.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,701
Open 3.01
Previous Close 2.98
Day's Range 2.80 - 3.15
52-Week Range 2.80 - 10.34
Beta 0.97
Analysts Buy
Price Target 33.00 (+1,037.93%)
Earnings Date Nov 8, 2023

About LPCN

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Mahesh V. Patel Ph.D.
Employees 15
Stock Exchange NASDAQ
Ticker Symbol LPCN
Full Company Profile

Financial Performance

In 2022, Lipocine's revenue was $500,000, a decrease of -96.90% compared to the previous year's $16.14 million. Losses were -$10.76 million, 1595.9% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for LPCN stock is "Buy" and the 12-month stock price forecast is $33.0.

Price Target
$33.0
(1,037.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

SALT LAKE CITY , Sept. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Pa...

8 days ago - PRNewsWire

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results f...

6 weeks ago - PRNewsWire

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P 1 in the LPCN 1148 treatment arm relative to placebo (P < 0.05) More patients on LPCN ...

2 months ago - PRNewsWire

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

SALT LAKE CITY , June 14, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platfo...

3 months ago - PRNewsWire

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY , June 7, 2023 /PRNewswire/ -- Li...

4 months ago - PRNewsWire

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression

Identified dosing regimen that enables reliance on a single confirmatory pivotal pharmacokinetic (PK) study to establish efficacy for postpartum depression (PPD) and support NDA submission LPCN 1154 t...

4 months ago - PRNewsWire

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023

SALT LAKE CITY , May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platfor...

5 months ago - PRNewsWire

First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154

LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression (PPD) Topline study results expected in H1 2023 SALT LAKE CITY , April 3, 2023 /PRNewswire/...

6 months ago - PRNewsWire

Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock

SALT LAKE CITY , March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of...

7 months ago - PRNewsWire

Lipocine Announces Financial Results for the Year Ended December 31, 2022

SALT LAKE CITY , March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary pla...

7 months ago - PRNewsWire

Lipocine to Present at Biotech Showcase

Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY , Jan. 5, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on...

9 months ago - PRNewsWire

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis

Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY , Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Cent...

10 months ago - PRNewsWire

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platf...

11 months ago - PRNewsWire

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

SALT LAKE CITY , Nov. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop differentiat...

11 months ago - PRNewsWire

Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference

SALT LAKE CITY , Oct. 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products throu...

1 year ago - PRNewsWire

Lipocine to Participate in the Cantor Neurology & Psychiatric Conference

SALT LAKE CITY , Sept. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products thro...

1 year ago - PRNewsWire

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders Initial focus on oral delivery of neu...

1 year ago - PRNewsWire

Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference

SALT LAKE CITY , Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment therapeutics through effecti...

1 year ago - PRNewsWire

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion brexanolone Lipocine has demonstrated that the brexanolone exposure...

1 year ago - PRNewsWire

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022

SALT LAKE CITY , Aug. 8, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") ...

1 year ago - PRNewsWire

FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment

Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022 SALT LAKE CITY, July 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative produ...

1 year ago - PRNewsWire

LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS

SALT LAKE CITY , June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Paten...

1 year ago - PRNewsWire

LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE

SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented ...

1 year ago - PRNewsWire

Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results

LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144 treatment Observed liver histology improveme...

1 year ago - PRNewsWire

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022

SALT LAKE CITY , May 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today annou...

1 year ago - PRNewsWire